Some tips on 5317-33-9

5317-33-9 3-(4-Methylpiperazin-1-yl)propan-1-ol 79208, apiperazines compound, is more and more widely used in various fields.

5317-33-9, 3-(4-Methylpiperazin-1-yl)propan-1-ol is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Di-tert-butyl azodicarboxylate (0.478 g, 2.08 mmol) was added portionwise to a mixture of product step 6 (1.66 mmol), the appropriate alcohol (1.74 mmol), and triphenyl-phosphine (0.544 g, 2.08 mmol) in dichloromethane (20 mL) at r.t. If necessary, further alcohol was added. After stirring for 2 h, the solution was concentrated to 10 mL, mounted on silica and chromatographed (gradient, dichloromethane to dichloromethane_methanol=3:2) to obtain the desired ethers (73%).The compound was synthesised according to GP 4 from 4-chloro-7-hydroxy-6-methoxy-quinazoline and 3-(4-methylpiperazin-1-yl)-propan-1-ol. LC/ESI-MS: m/z=351 [M+H]., 5317-33-9

5317-33-9 3-(4-Methylpiperazin-1-yl)propan-1-ol 79208, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; 4SC AG; US2006/135782; (2006); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Simple exploration of 21043-40-3

As the paragraph descriping shows that 21043-40-3 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.21043-40-3,1-Cyclopentylpiperazine,as a common compound, the synthetic route is as follows.

To a mixture of 3-(4-chlorobenzoyl)propionic acid (31.9 g, 150 mmol), DMF (200 ml), and N-hydroxybenzotriazole (40.6 g, 301 mmol) was added a solution of N-ethyl-/V-(3-dimethylaminopropyl)carbodiimide hydrochloride (28.8 g, 150 mmol) in DMF (100 ml). The mixture was stirred at room temperature for 1.5 hour, and a solution of 1-cyclopentylpiperazine (23.2 g, 150 mmol) in DCM (100 ml) was added. The mixture was stirred at room temperature for 4 hours, concentrated under reduced pressure, and the residue was distributed between ethyl acetate (1.0 I) and a saturated, aqueous NaHCO3 solution (1.0 I). Phases were separated, the organic layer was dried (MgSO4), and concentrated, and the residue was redissolved in 1 molar aqueous hydrochloric acid (150 ml). The solution was concentrated, and the residue was dried by coevaporation with ethanol. Recrystallization of the residue from ethanol yielded 31.1 g (54%) of the title compound. Concentration of the mother liquor gave additional 19.4 g (34%) of product., 21043-40-3

As the paragraph descriping shows that 21043-40-3 is playing an increasingly important role.

Reference£º
Patent; Dorwald, Florencio Zaragoza; Andersen, Knud Erik; Sorensen, Jan Lindy; US2004/19039; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Analyzing the synthesis route of 5271-27-2

The synthetic route of 5271-27-2 has been constantly updated, and we look forward to future research findings.

5271-27-2, 1-Methyl-3-phenylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

5271-27-2, Example 119 and 120lambda/-Cyclopropyl-4-methyl-3-[3-(4-methyl-2-phenyl-1-piperazinyl)-2-oxo-1(2H)- pyrazinylj-benzamide (Example 119) and 3-[5-bromo-3-(4-methyl-2-phenyl-1 – piperazinyl)-2-oxo-1(2H)-pyrazinyl]-lambda/-cyclopropyl-4-methyl-benzamide (Example 120).A mixture of 3-(3,5-dibromo-2-oxo-2/-/-pyrazin-1-yl)-4-methyl-benzoic acid, methyl ester (Example 1 b, 1 15 mg), 1-methyl-3-phenyl-piperazine (77 mg), lambda/,lambda/-diisopropylethylamine (0.1 mL) and tetrahydrofuran (1 mL) was heated within a microwave for 30 minutes at 100¡ãC before being cooled to room temperature. The mixture was transferred to a mixture of palladium on carbon (10percent, 50 mg) and tetrahydrofuran (1 mL) and 1 ,4-cyclohexadiene (1 mL) was added. The mixture was heated under atmosphere of nitrogen within a microwave for 2.5 h at 120¡ãC. An additional portion of palladium on carbon (50 mg) in tetrahydrofuran (1 mL) was added and the mixture was heated for 1 h at 120¡ãC. After cooling, cyclopropylamine (0.3 mL) was added followed by dropwise addition of a solution of /so-propylmagnesium chloride (2M in tetrahydrofuran, 2.5 mL). The mixture was stirred for 10 min. and quenched with sat. aqueous NH4CI and extracted into ethyl acetate. The organic phase was dried (Na2SO4), filtered and concentrated. Purification by preparative HPLC (Gemini column, 0.1 percent ammonia: acetonitrile eluent) afforded lambda/-cyclopropyl-4- methyl-3-(4-methyl-3′-oxo-2-phenyl-3,4,5,6-tetrahydro-2/-/,3’/-/-[1 ,2′]bipyrazinyl-4′-yl)- benzamide (49 mg) and 3-(6′-Bromo-4-methyl-3′-oxo-2-phenyl-3,4,5,6-tetrahydro-2/-/,3’/-/- [1 ,2′]bipyrazinyl-4′-yl)-lambda/-cyclopropyl-4-methyl-benzamide (8 mg).lambda/-Cyclopropyl-4-methyl-3-[3-(4-methyl-2-phenyl-1-piperazinyl)-2-oxo-1(2H)- pyrazinylj-benzamideMS: APCI(+ve) 444 (M+H+).1H NMR .5(DMSO-Cl6, 400MHz) 8.45 (1 H, m), 7.88-7.83 (1 H, m), 7.75 and 7.71 (1 H, 2 x d), 7.52 – 7.42 (3H, m), 7.37 – 7.28 (2H, m), 7.25 – 7.16 (1 H, m), 6.98 (2H, s), 6.17 and 6.07 (1 H, 2 x br s), 3.27 – 3.10 (1 H, m), 2.90 – 2.70 (2H, m), 2.48 – 2.37 (2H, m), 2.20 (3H, m), 2.15 (2H, m), 2.1 1 and 2.04 (3H, 2 x s), 0.69 (2H, m), 0.55 (2H, m).3-[5-Bromo-3-(4-methyl-2-phenyl-1-piperazinyl)-2-oxo-1(2H)-pyrazinyl]-lambda/- cyclopropyl-4-methyl-benzamideMS: APCI(+ve) 522 (M+H+). 1H NMR 5(DMSO-Cl6, 400MHz) 8.42 (1 H, m), 7.85 (1 H, m), 7.77 and 7.74 (1 H, 2 x d), 7.52 – 7.41 (3H, m), 7.37 – 7.28 (2H, m), 7.27 – 7.19 (2H, m), 6.28 and 6.16 (1 H, 2 x br s), 3.29 (3H, s), 3.18 – 3.03 (1 H, m), 2.89 – 2.72 (2H, m), 2.48 – 2.36 (1 H, m), 2.20 (3H, m), 2.15 and 2.07 (3H, 2 x s), 0.69 (2H, m), 0.55 (2H, m).

The synthetic route of 5271-27-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2009/1132; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Simple exploration of 13889-98-0

13889-98-0, 13889-98-0 1-Acetylpiperazine 83795, apiperazines compound, is more and more widely used in various fields.

13889-98-0, 1-Acetylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The compound of formula 38 (10.0 g, 49.2 mmol) was added to the reaction flask at room temperature,100 mL of N, N-dimethylacetamide,1-acetylpiperazine 16 (8.2 g, 64.0 mmol)N, N-diisopropylethylamine (19.1 g, 147.8 mmol)90 reaction 7 ~ 8h,TLC monitoring reaction is complete,Down to room temperature,The reaction solution was poured into 300 mL of water,Extracted with ethyl acetate (80 mL x 3)Combined organic layer,Washed with saturated brine,Dried over anhydrous sodium sulfate,The compound of formula 41 (9.9 g) was obtained by steaming,As a beige solid (yield 80.6%).

13889-98-0, 13889-98-0 1-Acetylpiperazine 83795, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; Zhengda Tianqing Pharmaceutical Group Co., Ltd.; Zhang Yinsheng; Gao Yong; Ren Jing; Wang Qinglin; Wang Zhao; (67 pag.)CN106905245; (2017); A;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Downstream synthetic route of 20327-23-5

20327-23-5, The synthetic route of 20327-23-5 has been constantly updated, and we look forward to future research findings.

20327-23-5, 1-Cyclopropylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 168 N-[2-(4-Cyclopropylpiperazin-1-yl)ethyl]-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]-pyridine-3-carboxamide 118 mg of 8-[(2,6-difluorobenzyl)oxy]-2-methyl-N-(2-oxoethyl)imidazo[1,2-a]pyridine-3-carboxamide (Example 194A, 0.16 mmol, 1 equivalent) were suspended in 0.8 ml of dry dichloroethane, 23 mg 1-cyclopropylpiperazine (0.18 mmol, 1.1 equivalents) were added and the mixture was stirred at RT for 3 h. 52 mg of sodium triacetoxyborohydride (0.25 mmol, 1.5 equivalents) were then added, and the mixture was stirred at RT overnight. 1 N aqueous sodium hydroxide solution was then added, and the mixture was extracted three times with dichloromethane. The combined organic phases were washed with water and saturated aqueous sodium chloride solution, dried over sodium sulphate, filtered and concentrated. The residue was dissolved in methanol and purified by preparative HPLC (method: RP18 column, mobile phase: acetonitrile/water gradient with addition of 0.1% TFA). The product fraction was taken up in ethyl acetate and washed twice with saturated aqueous sodium bicarbonate solution. The combined organic phases were dried over sodium sulphate, filtered and concentrated. This gave 33.5 mg (43% of theory) of the title compound. LC-MS (Method 7): Rt=0.60 min MS (ESpos): m/z=470.2 (M+H)+ 1H NMR (400 MHz, DMSO-d6): delta=0.22-0.30 (m, 2H), 0.34-0.43 (m, 2H), 1.53-1.62 (m, 1H), 2.30-2.44 (m, 3H), 3.37-3.46 (m, 2H), 5.30 (s, 2H), 6.93 (t, 1H), 7.01 (d, 1H), 7.23 (t, 2H), 7.55-7.64 (m, 1H), 7.70 (t, 1H), 8.67 (d, 1H), [further signals hidden under solvent peaks].

20327-23-5, The synthetic route of 20327-23-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BAYER PHARMA AKTIENGESELLSCHAFT; VAKALOPOULOS, Alexandros; FOLLMANN, Markus; HARTUNG, Ingo; BUCHGRABER, Philipp; JAUTELAT, Rolf; HAssFELD, Jorma; LINDNER, Niels; WUNDER, Frank; STASCH, Johannes-Peter; REDLICH, Gorden; LI, Volkhart Min-Jian; BECKER, Eva-Maria; KNORR, Andreas; US2014/128372; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Brief introduction of 122833-04-9

The synthetic route of 122833-04-9 has been constantly updated, and we look forward to future research findings.

122833-04-9, 2-Methoxy-4-(4-methylpiperazin-1-yl)aniline is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of the product of EXAMPLE SE (300 mg, 1.4 mmol), 2-methoxy-4-(4-methylpiperazin- 1 -yl) aniline (338 mg, 1.53 mmol) andtriethylamine (421 mg, 4.17 mmol) in 1,4-dioxane (30 mL) was stirred at 105 C. under nitrogen for 12 hours. The solvent was removed under vacuum and the residue was washed with sodium bicarbonate solution and ethanol. The crude product was recrystallized from 1 ,4-dioxane to give the title compound.10318] ?H NMR (DMSO-d5) oe ppm 12.66 (s, 1H), 11.35 (s, 1H), 8.31 (d, J=9.0 Hz, 1H), 8.25 (s, 1H), 6.68 (d, J=1.2 Hz, 1H), 6.54 (dd, J=1.2, 9.0 Hz, 1H), 3.89 (s, 3H), 3.21-3.10 (m, 4H), 2.50-2.44 (m, 4H), 2.25 (s, 3H)., 122833-04-9

The synthetic route of 122833-04-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ABBVIE INC.; Vasudevan, Anil; Penning, Thomas Dale; Chen, Huanming; Liang, Bo; Wang, Shaohui; Zhao, Zhongqiang; Chai, Dikun; Yang, Leifu; Gao, Yingxiang; Pliushchev, Marina; US2014/171429; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Brief introduction of 21043-40-3

21043-40-3 1-Cyclopentylpiperazine 806421, apiperazines compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.21043-40-3,1-Cyclopentylpiperazine,as a common compound, the synthetic route is as follows.

Example 58(4-cyclopentylpiperazin-1-yl)(7-(methylsulfonyl)-7-azaspiro[3.5]nonan-2-yl)methanone Oxalyl chloride (85 mul, 0.97 mmol) was slowly added to a solution of Intermediate 26 in DCM (12 mL) at 0 C. One drop of DMF was added and the reaction mixture was stirred for 4 h. The solvent was concentrated. The residue was quickly recovered in DCM (5 mL) and added to a solution of 1-cyclopentylpiperazine (54.9 mg, 0.36 mmol) and Et3N (0.135 mL, 0.97 mmol) in DCM (12 mL) at 0 C. The reaction mixture was allowed to warm to ambiant temperature and stirred for 1 h. The solvent was concentrated and the product was purified on silica gel (24 g) by MPLC using MeOH 5%, acetone 10% in DCM as eluent to provide title compound (106 mg, 85%) as a solid. 1H NMR (400 MHz, CHLOROFORM-d) delta ppm 1.32-1.47 (m, 2H) 1.49-1.62 (m, 2H) 1.64-1.73 (m, 4H) 1.73-1.80 (m, 2H) 1.80-1.92 (m, 2H) 1.97-2.07 (m, 2H) 2.10-2.20 (m, 2H) 2.40-2.55 (m, 5H) 2.76 (s, 3H) 3.07-3.14 (m, 2H) 3.15-3.26 (m, 3H) 3.32-3.39 (m, 2H) 3.59-3.67 (m, 2H); HRMS m/z calcd for C19H34N3O3S 384.2315 [M+H]+, found 384.2305., 21043-40-3

21043-40-3 1-Cyclopentylpiperazine 806421, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; ASTRAZENECA AB; US2010/130477; (2010); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Brief introduction of 169447-70-5

169447-70-5, As the paragraph descriping shows that 169447-70-5 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.169447-70-5,(S)-tert-Butyl 2-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

tert-Butyl (25)-2-methylpiperazine-1-carboxylate ( 43.1 g, 215 mmol) was added to asolution of aldehyde from Preparation 3 (39.0 g, 195 mmol) in dichloromethane (780mL). The reaction mixture was stirred at room temperature for 10 min then sodiumtriacetoxyborohydride (83.1 g, 391 mmol) was added portion-wise. On complete30 addition the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was carefully quenched with water (200 mL) and extracted withdichloromethane (200 mL). The organic layer was dried over sodium sulphate andconcentrated under reduced pressure. Trituration of the crude product with n-pentane afforded the title compound as an off-white solid. (43.0 g, 57.3%)5 1H NMR (300MHz, DM50-d6) o =7.92 (d, 1=2.2 Hz, lH), 7.68 (d, 1=2.2 Hz, lH), 4.09(m, lH), 3.67 (br d, J= 13.1 Hz, lH), 3.52 (s, 2H), 2.88-3.02 (m, lH), 2.69 (br d,J=ll.l Hz, lH), 2.57 (br d, 1=11.3 Hz, lH), 2.35 (s, 3H), 2.15 (dd, 1=11.3, 3.6 Hz, lH),1.98 (td, 1=11.7, 3.4 Hz, lH), 1.39 (s, 9H), 1.13 (d, J=6.7 Hz, 3H). LCM5 Method 1:10m/z 384.66 [M+H+]; RT = 3.47 min

169447-70-5, As the paragraph descriping shows that 169447-70-5 is playing an increasingly important role.

Reference£º
Patent; LEO PHARMA A/S; JESSIMAN, Alan Stuart; JOHNSON, Patrick Stephen; MAANSSON, Kristoffer; S?RENSEN, Morten Dahl; (156 pag.)WO2018/11201; (2018); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Brief introduction of 414910-15-9

414910-15-9, As the paragraph descriping shows that 414910-15-9 is playing an increasingly important role.

414910-15-9, tert-Butyl 4-(cyclopropanecarbonyl)piperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1 -Tertbutoxycarbonyl-4-(cyclopropanecarbonyl)piperazine (190 mg, 0.75 mmol) was dissolved in dichloromethane, and then trifluoroacetic acid (1 mE) was added. The reaction mixture was stirred at room temperature until complete reaction, and then washed with saturated sodium bicarbonate solution for three times. The organic phases were concentrated to give 112mg (yield 97%) pale yellow solid of N-(cyclopropanecarbonyl) piperazine for use.

414910-15-9, As the paragraph descriping shows that 414910-15-9 is playing an increasingly important role.

Reference£º
Patent; CHENGDU DI’AO PHARMACEUTICAL GROUP CO., LTD.; Ji, Jianxin; Guo, Na; Xue, Ting; Kang, Bingqiang; Ye, Xinfa; Chen, Xin; Zhang, Tao; US2015/51211; (2015); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

New learning discoveries about 1188265-73-7

As the paragraph descriping shows that 1188265-73-7 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1188265-73-7,tert-Butyl 3-(2-hydroxyethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

To a solution of Intermediate 4 (0.38 g, 2.06 mmol) in DMF (20 mL) were added tert-butyl 3-(2-hydroxyethyl)piperazine-l-carboxylate (1 g, 4.12 mmol) and DIPEA (0.4 g, 3.0 mmol). The reaction mixture was heated at 100C for 5 h, allowed to cool, then stirred at room temperature for 2 days. The reaction mixture was concentrated in vacuo, then partitioned between water and DCM. The organic phase was separated and concentrated in vacuo. The resulting crude material was purified by column chromatography (silica gel: 100-200 mesh, MeOH:DCM gradient 0% to 20%) to give a pale yellow foam. The foam was dissolved in DCM (1 mL) and TFA (2 mL) and stirred for 1 h. The reaction mixture was concentrated in vacuo, then triturated with diethyl ether, to give the title compound (0.6 g) as a sticky yellow solid., 1188265-73-7

As the paragraph descriping shows that 1188265-73-7 is playing an increasingly important role.

Reference£º
Patent; UCB PHARMA S.A.; KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D; BROOKINGS, Daniel Christopher; FORD, Daniel James; FRANKLIN, Richard Jeremy; GHAWALKAR, Anant Ramrao; KULISA, Claire Louise; NEUSS, Judi Charlotte; REUBERSON, James Thomas; WO2013/68458; (2013); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics